Clinical Trend of the Week (October 28-November 3): Shingrix Vaccine
A newly approved vaccine designed to help older adults battle a painful disease is this week's top search term. The US Food and Drug Administration recently approved GlaxoSmithKline's recombinant zoster vaccine (Shingrix) for the prevention of herpes zoster (shingles) in adults age 50 years and older. The vaccine is given in two doses, with 2-6 months between doses, and is intended to generate a response that can overcome declining immunity associated with age. In addition, the federal government's Advisory Committee on Immunization Practices (ACIP) narrowly voted to recommend Shingrix over a live, attenuated virus shingles vaccine in adults age 50 years and older. Although the vote to recommend was 8 to 7, the group indicated the close margin was more of a response to Shingrix having been so recently approved than to confidence in the vaccine. With efficacy estimates of 97% in adults aged 60-69 years and 91% in those aged 70-79 years, optimism is high, as are searches for this week's top term.
.png)
For more information on shingles, read here.
Medscape © 2017
WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ryan Syrek. Clinical Trends for November 2017 - Medscape - Dec 01, 2017.
Comments